Vericel (VCEL) is a commercial-stage biopharma company that focuses on sports medicine and severe burn care therapies. President and CEO, Nick Colangelo discusses VCEL as it expects an accelerated commercial launch for arthroscopic Maci. he notes that VCEL anticipates an accelerated potential commercial launch of arthroscopic Maci in 2024. He then goes over how VCEL announced FDA approval of Nexobird, U.S. commercial availability expected in 2Q23. Tune in to find out more about the stock market today.
20 Jan 2023
The Watch List
22 Jan 2023
Market On Close
23 Jan 2023
Morning Trade Live
14 Nov 2022
The Watch List
21 Nov 2022
The Watch List
09 Dec 2022
The Watch List
17 Nov 2022